{"meshTags":["Carcinoma, Bronchogenic","Cyclophosphamide","Drug Therapy, Combination","Podophyllotoxin","Male","Lung Neoplasms","Humans","Female","Etoposide"],"meshMinor":["Carcinoma, Bronchogenic","Cyclophosphamide","Drug Therapy, Combination","Podophyllotoxin","Male","Lung Neoplasms","Humans","Female","Etoposide"],"organisms":["50455","50455"],"publicationTypes":["Journal Article"],"abstract":"Thirty-two patients with by non oat cell bronchogenic carcinoma were admitted to a protocol including Cyclophosphamide (CTX) 1,000 mg/m2 i.v. day 1, VP16-213 200 mg/m2 p.o. day 1-3, every 3 weeks. Partial remissions were seen in 2 of 27 evaluable patients; 16 of 27 showed no change. Mean survival was 36.4 weeks, median survival was 38 weeks.","title":"VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma.","pubmedId":"7083461"}